Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Devices Account For 6.2% Of Health Expenditures, AdvaMed Study Finds

This article was originally published in The Gray Sheet

Executive Summary

As congressional reformers look for ways to cut health care costs, AdvaMed aims to raise awareness that medical devices and diagnostics represent only a single-digit share of national health care expenditures
Advertisement

Related Content

News In Brief
News In Brief
Implantable Device Pricing, Utilization Are Under GAO's Microscope
Implantable Device Pricing, Utilization Are Under GAO's Microscope
House Bills Seek Transparency In Health Care Pricing
AdvaMed Floats Human Factors Design As Industry Cost-Containment Strategy
Device Costs Are Under Control, AdvaMed Says In New Report
Device Costs Are Under Control, AdvaMed Says In New Report
Pricey Technology Is Key Driver Of Health Costs – Congressional Budget Offc.
Device Firms Would Have To Report Sales Prices To CMS Under Senate Bill

Topics

Advertisement
UsernamePublicRestriction

Register

MT027497

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel